A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
NCT00238654 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 257
Last updated 2011-04-12
Summary
This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection. In addition, patients will have their self-injection observed and evaluated on up to three visits
Conditions
Sponsors & Collaborators
-
Teva Neuroscience, Inc.
lead INDUSTRY
Principal Investigators
-
MerriKay Oleen-Burkey, Ph.D. · Teva Neuroscience, Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-05-31
- Primary Completion
- 2008-07-31
- Completion
- 2008-07-31
More Related Trials
-
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
NCT00203086 ·Status: COMPLETED
-
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
NCT01167426 ·Status: COMPLETED ·Phase: PHASE3
-
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
NCT00915577 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
NCT03822858 ·Status: AVAILABLE
-
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
NCT00203112 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
NCT00828204 ·Status: COMPLETED ·Phase: PHASE3
-
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
NCT00001669 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
NCT02499900 ·Status: COMPLETED ·Phase: PHASE4
-
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
NCT00245622 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
NCT00203073 ·Status: COMPLETED ·Phase: PHASE2
-
Avonex PEN Satisfaction and Patients Experience Clinical Trial
NCT01366040 ·Status: COMPLETED
-
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
NCT00202982 ·Status: COMPLETED ·Phase: PHASE2
-
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
NCT00292253 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
NCT01036165 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration
NCT01195857 ·Status: COMPLETED
-
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
NCT00203099 ·Status: COMPLETED ·Phase: PHASE2
-
A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS)
NCT02846558 ·Status: COMPLETED ·Phase: NA
-
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203021 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses
NCT01900093 ·Status: UNKNOWN ·Phase: NA
-
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
NCT02284568 ·Status: COMPLETED ·Phase: PHASE2
-
Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
NCT03355365 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
NCT05232825 ·Status: COMPLETED ·Phase: PHASE3
-
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT02398461 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
NCT01888354 ·Status: COMPLETED ·Phase: PHASE4